Prescription eye drops recalled for particulate matter contamination
Sun Pharmaceutical recalls Xelpros latanoprost eye drops (Lot HAD3383A) due to particulate matter contamination detected during release testing. Affected bottles were distributed in Texas and Pennsylvania.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III recall with no reported illnesses or injuries. The hazard—particulate matter detected in quality control testing—is theoretical, representing a contamination issue warranting a Moderate classification per the rubric guidance that Class III recalls are typically scored 1 or 2.
Plain-English summary
Xelpros (latanoprost ophthalmic emulsion) 0.005% is a prescription eye medication used to treat elevated eye pressure. Sun Pharmaceutical Industries Inc is recalling approximately 35,069 bottles with Lot number HAD3383A and expiration date August 31, 2024.
The recall was initiated following failed release testing, during which the medication was found to be out of specification for particulate matter. This indicates the presence of particles in the eye drop solution that should not be present.
The affected bottles were distributed in Texas and Pennsylvania. Patients currently using this medication should contact their healthcare provider or pharmacist to determine if they have a recalled bottle and discuss appropriate next steps.
The recalled product
- Product
- XELPROS (LATANOPROST)
- Brand
- XELPROS
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug — Ophthalmic
- Hazard
- Affected units
- 35,069
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: HAD3383A
- Exp 8/31/2024
Distribution
Related recalls
Same manufacturer · SUN PHARMACEUTICAL INDUSTRIES INC
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · particulate matter
See all →- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereACTHAR Gel Recalled for Presence of Glass and Stopper Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereAmerican Regent Recalls Nitroglycerin Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Atropine Sulfate Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Multrys Trace Elements Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26